Today: 20 March 2026
Browse Category

Stock Market 15 January 2026

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck shares fell 0.2% to $110.75 Thursday after the FDA delayed decisions in its new voucher fast-track program, according to Reuters. The FDA postponed reviews of drugs from Sanofi, Disc Medicine, and Eli Lilly, citing safety concerns. Investors are watching for Merck’s Feb. 3 earnings and updates on its drug pipeline. Healthcare stocks broadly declined, with Eli Lilly down 3.6%.
Amphenol (APH) stock jumps 6% as Goldman lifts target and company tees up ADC India open offer

Amphenol (APH) stock jumps 6% as Goldman lifts target and company tees up ADC India open offer

Amphenol shares jumped 6.4% to $156.13 after the company filed an open offer to buy 26% of ADC India, following its $10.5 billion CommScope deal. Goldman Sachs, BofA, and UBS raised price targets, citing strong data-center demand. The open offer totals about $16.4 million if fully accepted. Investors await Amphenol’s Jan. 28 earnings call for updates on integration and order trends.
15 January 2026
Bloom Energy stock jumps 8% as EIA flags data-center power surge

Bloom Energy stock jumps 8% as EIA flags data-center power surge

Bloom Energy shares jumped 8% to $144.11 Thursday, hitting a new intraday high amid investor focus on rising electricity demand from data centers. The move follows American Electric Power’s $2.65 billion deal to buy Bloom’s fuel cells for a Wyoming facility. Broader clean energy stocks also rose, while Bloom’s rivals fell. The EIA will release updated U.S. energy demand forecasts on February 10.
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares rose 0.3% to $25.67 Thursday as investors weighed U.S. vaccine policy debates and the company’s growth outlook. The stock moved between $25.26 and $25.67 with 22.3 million shares traded. Pfizer will report Q4 results on Feb. 3, with guidance projecting 2026 revenue of $59.5–$62.5 billion and lower COVID-19 product sales. Competition in obesity drugs and AI-driven drug discovery remain in focus.
Morgan Stanley stock jumps as Wall Street deal talk returns after Q4 earnings

Morgan Stanley stock jumps as Wall Street deal talk returns after Q4 earnings

Morgan Stanley shares rose 5.9% to $191.41 after reporting fourth-quarter net revenues of $17.89 billion and earnings of $2.68 per share. Investment banking revenue reached $2.41 billion, and net new assets in wealth management totaled $122.3 billion. The board declared a $1.00 quarterly dividend and repurchased $1.5 billion in stock. Investors focused on rising deal activity and the upcoming Federal Reserve meeting.
Silverstock Metals stock jumps 20% as silver’s record run whipsaws traders

Silverstock Metals stock jumps 20% as silver’s record run whipsaws traders

Silverstock Metals (CSE:STK) jumped 20% to C$0.24 in thin Thursday trading, tracking silver’s volatile run after the metal hit a record $93.57 an ounce before sliding 2.4%. TD Securities closed a short silver position after losses, citing strong demand and supply issues. Silverstock holds exploration claims in British Columbia but does not produce metal. Investors are watching Fed policy signals and upcoming data.
15 January 2026
Coinbase stock slides as Senate delays crypto bill, putting bitcoin-linked shares back on edge

Coinbase stock slides as Senate delays crypto bill, putting bitcoin-linked shares back on edge

Coinbase shares fell 3.3% Thursday after the Senate Banking Committee delayed a crypto market-structure bill markup. Bitcoin slipped 0.6% to $96,418, pulling down related stocks. The delay followed Coinbase’s withdrawal of support for the draft, with CEO Brian Armstrong citing concerns over stablecoin rewards and regulatory limits. Traders are watching for signs of a rescheduled committee vote.
Caterpillar stock rises as new Construction Industries chief named, AI power demand stays in focus

Caterpillar stock rises as new Construction Industries chief named, AI power demand stays in focus

Caterpillar shares rose 1.8% to $650.46 Thursday afternoon, nearing record highs as investors focused on data-center power demand. The company said Rod Shurman will become head of Construction Industries on Feb. 1, following Tony Fassino’s planned retirement. Caterpillar’s market cap briefly topped $300 billion earlier in the week.
Morgan Stanley stock jumps nearly 6% after earnings beat and dividend lift

Morgan Stanley stock jumps nearly 6% after earnings beat and dividend lift

Morgan Stanley shares jumped 5.9% to $191.39 Thursday after the bank reported fourth-quarter earnings of $2.68 per share and a $1.00 dividend. Investment banking revenue rose 47% to $2.41 billion, driven by a surge in debt underwriting. The bank also repurchased $1.5 billion in stock. Investors are watching the deal pipeline and upcoming Federal Reserve meeting for signs of sustained momentum.
Lockheed Martin stock today: UBS lifts target to $580 as defense investors shift focus to budgets and earnings

Lockheed Martin stock today: UBS lifts target to $580 as defense investors shift focus to budgets and earnings

Lockheed Martin shares traded flat at $573.37 Thursday after UBS raised its price target to $580 but kept a Neutral rating. L3Harris surged to record highs as the Pentagon committed $1 billion to its missile motor unit ahead of a planned spinoff. Lockheed’s next earnings call is set for Jan. 29. Investors remain focused on defense supply chain moves and policy signals from Washington.
EchoStar stock drops nearly 3% as Crown Castle seeks $3.5 billion from Dish Wireless

EchoStar stock drops nearly 3% as Crown Castle seeks $3.5 billion from Dish Wireless

EchoStar shares dropped 2.9% to $127.24 in midday trading Thursday after Crown Castle terminated a Dish Wireless agreement and said it will pursue over $3.5 billion in payments. The dispute comes as EchoStar restructures its wireless business and sells spectrum to SpaceX. Traders are watching FCC deadlines tied to SpaceX’s planned satellite-to-phone service using EchoStar spectrum.
High Roller Technologies stock jumps again as ROLR adds Lines.com marketing plan to Crypto.com prediction push

High Roller Technologies stock jumps again as ROLR adds Lines.com marketing plan to Crypto.com prediction push

Shares of High Roller Technologies soared 44% to $27.20 in Thursday afternoon trading, extending a two-day rally sparked by a partnership with Crypto.com for U.S. prediction markets. The stock surged 436% Wednesday after the deal was announced. High Roller also disclosed a separate letter of intent with sports media firm Lines.com. Investors await details on the planned Q1 2026 U.S. launch.
Texas Instruments stock slips despite chip rally as Barclays, Wells Fargo and Citi reset targets

Texas Instruments stock slips despite chip rally as Barclays, Wells Fargo and Citi reset targets

Texas Instruments shares fell 0.8% to $191.87 by midday Thursday, lagging the semiconductor sector’s rally. Barclays and Wells Fargo raised price targets but kept cautious ratings, while Citi maintained a Buy. Investors await Texas Instruments’ earnings on Jan. 27 for signals on demand outside AI chips. Analog Devices and ON Semiconductor both gained, contrasting Texas Instruments’ decline.
CrowdStrike (CRWD) stock rises after judge tosses outage lawsuit, Seraphic deal in focus

CrowdStrike (CRWD) stock rises after judge tosses outage lawsuit, Seraphic deal in focus

CrowdStrike shares rose 1.2% to $466.07 after a U.S. judge dismissed a shareholder fraud lawsuit linked to its July 2024 outage. The court found investors failed to show executives made false statements or intended fraud. CrowdStrike is also expanding into browser and identity security through new acquisitions. Investors are watching for updates on deal closings and upcoming earnings.
15 January 2026

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Go toTop